Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Hybrigenics    ALHYG   FR0004153930

HYBRIGENICS (ALHYG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Latest news on HYBRIGENICS
04/26HYBRIGENICS : Annual results
CO
2017HYBRIGENICS : rsquo; compound inhibits Ubiqitin-Specific Protease 10 (USP10) and..
PU
2017HYBRIGENICS : Télécharger le document associé Meet Hybrigenics Pharma at SOHO 20..
PU
2017HYBRIGENICS : gets European patent protection for inhibitors of Ubiquitin-Specif..
PU
2017HYBRIGENICS : full year 2016 results
PU
2017HYBRIGENICS : Strategic refocusing on biopharmaceutical R&D
PU
2017HYBRIGENICS : Encouraging preliminary results of the Phase II clinical study of ..
PU
2017HYBRIGENICS' : patent estate of inhibitors of ubiquitin specific proteases conti..
PU
2016HYBRIGENICS : rsquo; inecalcitol strengthens key patent protection in the United..
PU
2016HYBRIGENICS : receives green light for a double-blind placebo-controlled Phase I..
PU
2014HYBRIGENICS : 2014 first-half results and highlights
PU
2014HYBRIGENICS : successfully raised € 4.6 million
PU
2014HYBRIGENICS : invests in its genomic capabilities
PU
2014HYBRIGENICS' : patent estate of inhibitors of ubiquitin-specific proteases is ex..
PU
2014HYBRIGENICS : revenus et trésorerie au premier semestre 2014
PU
2013HYBRIGENICS : Hybrigenics' General Meeting highlights - Focus on inecalcitol rec..
PU
2013HYBRIGENICS : Update on the clinical study of inecalcitol in chronic lymphocytic..
PU
2013HYBRIGENICS : Hybrigenics' technology platform applied to the study of the aging..
PU
2013HYBRIGENICS : Hybrigenics' Technology Platform Successfully Applied to the Study..
BU
2013HYBRIGENICS : 2012 revenues and update on the clinical study of inecalcitol in c..
PU
2013HYBRIGENICS : launches a new service to screen interactions between small molecu..
PU
2012HYBRIGENICS : green ligt for two European patents protecting new oral formulatio..
PU
2012HYBRIGENICS : launches a new website
PU
2012HYBRIGENICS : Hybrigenics' first half 2012 revenues of EUR 2 million at the same..
PU
2012HYBRIGENICS : Hybrigenics' General Meeting Highlights
PU
2012HYBRIGENICS : Bryan, Garnier & Co initiates coverage of Hybrigenics with a targe..
BU
2012HYBRIGENICS : Bryan Garnier initiates coverage of Hybrigenics with a target pric..
PU
2012HYBRIGENICS : completed its private placement to institutional investors up to E..
PU
2012HYBRIGENICS : gets approval and financing for a phase II clinical trial of oral ..
PU
Financials (€)
Sales 2018 1,78 M
EBIT 2018 -5,14 M
Net income 2018 -5,03 M
Finance 2018 1,54 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 12,5x
EV / Sales 2019 25,0x
Capitalization 23,8 M
Chart HYBRIGENICS
Duration : Period :
Hybrigenics Technical Analysis Chart | ALHYG | FR0004153930 | 4-Traders
Technical analysis trends HYBRIGENICS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 1,11 €
Spread / Average Target 117%
EPS Revisions
Managers
NameTitle
Rémi Delansorne Chairman & Chief Executive Officer
Guillaume Floch Chief Financial Officer
Jean-François Dufour-Lamartinie Head-Clinical Research & Development
Piet Serrure Independent Director
Albert Saporta Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
HYBRIGENICS-17.74%28
CELLTRION, INC.--.--%33 987
IQVIA HOLDINGS INC5.50%21 394
LONZA GROUP3.38%20 341
INCYTE CORPORATION-21.91%15 677
ALNYLAM PHARMACEUTICALS, INC.-15.15%10 836